Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
113 hedge funds and large institutions have $642M invested in Adverum Biotechnologies in 2015 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 15 closing their positions.
210% more call options, than puts
Call options by funds: $13.4M | Put options by funds: $4.33M
200% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 15
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
35% more funds holding
Funds holding: 84 → 113 (+29)
11% less capital invested
Capital invested by funds: $719M → $642M (-$76.8M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$21.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$16.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$16M |
| 4 |
RIM
RS Investment Management
San Francisco,
California
|
+$14.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$35.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$21.1M |
| 3 |
CI
Cowen Inc
New York
|
-$13.4M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$11.7M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$9.9M |
ADVM Hedge Fund Activity: Q1 2015 in Review
113 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q1 2015, worth a combined $642M — down 11% from $719M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ADVM positions and 15 closed out — a net gain of 30 holders — while 37 added to existing stakes and 22 trimmed.
The largest buyer was Deerfield Management, adding an estimated $21.3M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $35.1M sold.
- 113 institutional investors held Adverum Biotechnologies (ADVM) as of Q1 2015, up from 84 in Q4 2014.
- Funds reported $642M of Adverum Biotechnologies stock for Q1 2015, down 11% quarter-over-quarter.
- 45 funds opened new Adverum Biotechnologies positions in Q1 2015 and 15 closed out, a net change of +30 holders.
- The largest Adverum Biotechnologies buyer in Q1 2015 was Deerfield Management, an estimated $21.3M added.
- The largest Adverum Biotechnologies seller in Q1 2015 was Adage Capital Partners, an estimated $35.1M sold.
Based on aggregated 13F filings for Q1 2015.